SCHEMBL4023313

SCHEMBL4023313

CC(C)Oc1ccc(-n2c(C(=O)O)c(-c3cccnc3)c3cc(-c4ccc(C(F)(F)F)cc4)ccc32)cn1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGES O14684 2/20 0.40
FFAR1 O14842 1/20 0.37
PPARG P37231 4/20 0.37
PPARA Q07869 3/20 0.37
PPARD Q03181 1/20 0.37
CYP3A4 P08684 1/20 0.36
CYP3A5 P20815 1/20 0.36
PTPN11 Q06124 1/20 0.36
MKNK1 Q9BUB5 1/20 0.36
MKNK2 Q9HBH9 1/20 0.36
KDR P35968 1/20 0.36
CYP11B1 P15538 1/20 0.36
CYP11B2 P19099 1/20 0.36
L3MBTL1 Q9Y468 2/20 0.35
LMNA P02545 1/20 0.35
MAPT P10636 1/20 0.35
XBP1 P17861 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
PLK1 P53350 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4189990 0.92 NR4A2 (0.41) PTGESFFAR1PPARAPPARDCYP3A4
SCHEMBL4023999 0.90 PPARD (0.38) FFAR1PPARAPPARDCYP3A4CYP3A5
SCHEMBL4021877 0.85 PTGES (0.46) PTGESPPARGPPARAPPARDPTPN11
SCHEMBL4021807 0.81 PTGES (0.60) PTGESPPARGPPARA
Hydrochloric Acid SCHEMBL4021808 0.80 PTGES (0.59) PTGESPPARGPPARA
SCHEMBL4024171 0.78 PTGES (0.58) PTGESPPARGPPARACYP3A4CYP3A5
SCHEMBL5230129 0.76 S1PR1 (0.37) MKNK1MKNK2MAPTSMN1; SMN2PLK1
SCHEMBL4026661 0.76 F2RL3 (0.40) PTGESPPARGPPARAPPARDCYP3A4
SCHEMBL3580289 0.73 PTGES (0.43) PTGES
SCHEMBL334036 0.73 PTGES (0.49) PTGESPPARGPPARAPTPN11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1765775-B1 INDOLES USEFUL IN THE TREATMENT OF INFLAMMATION BIOLIPOX AB (SE) 2009-04-29 EP disclosed
US-20080146616-A1 Indoles Useful in the Treatment of Inflammation BIOLIPOX AB (SE) 2008-06-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080146616-A1 Indoles Useful in the Treatment of Inflammation IDO1, PTGS1, PTGER1 PTGES 4/4885FFAR1 265/4885PPARG 693/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.